Clinical Trials Logo

Recurrent Uterine Carcinosarcoma clinical trials

View clinical trials related to Recurrent Uterine Carcinosarcoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03552471 Active, not recruiting - Clinical trials for Recurrent Ovarian Carcinoma

Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Start date: July 12, 2018
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of mirvetuximab soravtansine and rucaparib camsylate in treating participants with endometrial, ovarian, fallopian tube or primary peritoneal cancer that has come back. Drugs such as mirvetuximab soravtansine are antibodies linked to a toxic substance and may help find certain tumor cells and kill them without harming normal cells. Rucaparib camsylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving mirvetuximab soravtansine and rucaparib camsylate may work better in treating participants with recurrent endometrial, ovarian, fallopian tube or primary peritoneal cancer.